Biomarkers of Endometrial Receptivity

This clinical research study will investigate whether the expression of certain genes in the endometrium (the lining of the uterus) can predict in-vitro fertilization (IVF) success. The study will be looking at two specific genes, SIRT1 and BCL6, and whether their activity in the endometrium is correlated with IVF success.

Who is eligible to participate?

  • Ages 18 to 42
  • Normal ovarian reserve testing
  • Planning to undergo IVF preimplantation genetic testing for aneuploidy (PGT-A) with delayed embryo transfer
  • Normal endometrial thickness at time of human chorionic gonadotropin trigger

What factors would prevent a person from participating?

  • Uterine fibroids (intramural) > 4 cm in size
  • Uncorrected abnormal uterine cavity (abnormalities that are corrected to normal cavity are OK)
  • Polycystic ovary syndrome
  • Primary ovarian insufficiency
  • Subjects receiving donor oocytes/embryos
  • Failure to identify at least one euploid embryo (an embryo with a normal number of chromosomes) for frozen embryo transfer (FET)
  • Anti-cardiolipid and/or lupus anti-coagulant abnormalities by history
  • Diabetes mellitus (type 1 or type 2)
  • Untreated hypothyroidism
  • Hyperprolactinemia
  • BMI ≤ 17 and ≥ 35
  • Two or more prior failed embryo transfers
  • Translocation carrier

Study participation involves:

  • Agree to take progesterone luteal support after retrieval up until time of biopsy
  • Endometrial biopsy (EMB) one week after oocyte retrieval
  • Peripheral blood collection day of EMB
  • Follow outcome of FET

Patients receive payment for completing the EMB. They are informed of the results of the EMB after completing the FET.

For more information, please contact:

Fertility and Reproductive Health logo